Learning Objectives

Upon completion of this educational activity, participants will be able to: 
  • Raise awareness of Lipids as a major risk factor for cardiovascular disease in the regionExplore major causes of dyslipidemia in the population including diet and inheritance
  • Recognize the role of drug therapy in the management of dyslipidemia
  • Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders
  • Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
  • Describe the appropriate use of lipid-altering drugs in special populations
  • Identify lipid-lowering therapeutic approaches for older adults
  • Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management
  • Describe effective diet and lifestyle (exercise, weight management) strategies for the management of dyslipidemia and cardiovascular risk
  • Outline current guidelines on the management and treatment of patients with dyslipidemia
  • Compose a clinical care plan for reducing risk of CVD in patients with dyslipidemia
  • Analyze case studies in lipid management to improve treatment and prevention of cardiovascular disease
  • Analyze lipid cases for health professionals seeing patients with complex disorders
  • Identify the management of dyslipidemia in special populations based on gender, culture, and disease variables
  • Explain how obesity and adiposopathy contribute to the metabolic syndrome and diabetes mellitus
  • Identify management strategies for the cardiometabolic risk factors of the metabolic syndrome
  • Review the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of lipid disorders
  • Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
  • Review clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
  • Describe combination therapies for the management of complex lipid disorders and residual risk
  • Manage complex dyslipidemia and dyslipidemia in special populations